Feng Chi Biotech

Feng Chi Biotech Current Assets

The Current Assets of Feng Chi Biotech (6744.TWO) as of Oct 27, 2026 is 35.19 M TWD. In the previous year, Current Assets was 246.32 M TWD — a change of -85.72% (lower).

Current Assets

35.19 MTWD

YoY

-85.72%

Last updated:

Current Assets of Feng Chi Biotech is 2025 35.19 M TWD. Current Assets of Feng Chi Biotech was 2024 246.32 M TWD. It decreases by -85.72% lower compared to the previous year.

The Feng Chi Biotech Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
212.59 M TWD
Jan 1, 2019
239.38 M TWD
Jan 1, 2020
260.46 M TWD
Jan 1, 2021
266.03 M TWD
Jan 1, 2022
275.22 M TWD
Jan 1, 2023
255.21 M TWD
Jan 1, 2024
246.32 M TWD
Jan 1, 2025
35.19 M TWD
The Feng Chi Biotech Current Assets history
YEARCurrent AssetsYoY
35.19 MTWD-85.72%
246.32 MTWD-3.48%
255.21 MTWD-7.27%
275.22 MTWD+3.45%
266.03 MTWD+2.14%
260.46 MTWD+8.80%
239.38 MTWD+12.60%
212.59 MTWD+36.97%
155.21 MTWD+4.20%
148.95 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Feng Chi Biotech Stock analysis

What does Feng Chi Biotech do? Feng Chi Biotech Corp. generates revenue through the sale of prenatal and neonatal testing reagents and instruments, genetic testing analysis and development services, research instruments and reagents, and industrial microbiology and food testing reagents. The company's products are primarily sold to markets in Taiwan, China mainland, Japan, South Korea, Southeast Asia, and India, as well as other overseas regions. These services and products target healthcare providers, research institutions, and food safety regulators within these regions. The firm focuses on delivering comprehensive testing solutions across life science and microbiological applications for both clinical and industrial use cases. The company's product portfolio includes specialized reagents and instruments for prenatal and newborn screening, genetic analysis, and microbiological testing. These offerings are tailored to meet the needs of healthcare facilities and laboratories in the specified geographic markets. By providing end-to-end testing services and equipment, Feng Chi Biotech Corp. serves the growing demand for accurate diagnostic tools in reproductive health, genetic research, and food safety sectors. Feng Chi Biotech Corp. operates within the life science and microbiological testing services sector, offering a range of products that support prenatal care, neonatal screening, genetic research, and industrial food testing. The company's international sales strategy targets key regions in Asia, including Taiwan, China mainland, Japan, South Korea, Southeast Asia, and India, where healthcare and food safety regulations require regular testing. Their business model centers on providing reliable diagnostic solutions to medical and industrial clients across these markets. Feng Chi Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Feng Chi Biotech stock

Current Assets of Feng Chi Biotech is 35.19 M TWD in 2025.

Current Assets of Feng Chi Biotech changed from 246.32 M TWD to 35.19 M TWD, representing a -85.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Feng Chi Biotech since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Feng Chi Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Feng Chi Biotech

All Key Metrics — Feng Chi Biotech